528 related articles for article (PubMed ID: 36129669)
1. Release of Cervical Muscle Tension Improves Psychological Stress and Symptoms of Moderate-to-Severe Atopic Dermatitis: a Case Series with 20 Patients.
Hosono S; Fujita K; Nimura A; Akita K
Dermatol Ther (Heidelb); 2022 Oct; 12(10):2383-2395. PubMed ID: 36129669
[TBL] [Abstract][Full Text] [Related]
2. Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series.
Hosono S; Fujita K; Nimura A; Akita K
JAAD Case Rep; 2020 Jun; 6(6):510-513. PubMed ID: 32490112
[No Abstract] [Full Text] [Related]
3. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI
Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
8. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
Kimball AB; Delevry D; Yang M; Chuang CC; Wang Z; Bégo-Le-Bagousse G; Martins B; Wu E; Shumel B; Wang J; Sierka D; Chao J; Strober B
Dermatol Ther (Heidelb); 2023 Sep; 13(9):2107-2120. PubMed ID: 37552431
[TBL] [Abstract][Full Text] [Related]
9. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
Simpson EL; Guttman-Yassky E; Margolis DJ; Feldman SR; Qureshi A; Hata T; Mastey V; Wei W; Eckert L; Chao J; Arnold RJG; Yu T; Vekeman F; Suárez-Fariñas M; Gadkari A
JAMA Dermatol; 2018 Aug; 154(8):903-912. PubMed ID: 29971354
[TBL] [Abstract][Full Text] [Related]
10. Alterations in Brain Neural Network and Stress System in Atopic Dermatitis: Novel Therapeutic Interventions.
Nakagawa Y; Yamada S
J Pharmacol Exp Ther; 2023 May; 385(2):78-87. PubMed ID: 36828629
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
12. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study.
Gkalpakiotis S; Kannenberg S; Kingo K; Nada HR; Rakhmatulina MR; Lesiak A; Nicolescu AC; Darlenski R; Masri A; Zhou L; Albuquerque T; Hammad S; Almasry I
Dermatol Ther (Heidelb); 2024 May; 14(5):1173-1187. PubMed ID: 38702528
[TBL] [Abstract][Full Text] [Related]
13. Therapy of atopic eczema.
Werfel T; Claes C; Kulp W; Greiner W; von der Schulenburg JM
GMS Health Technol Assess; 2006 Oct; 2():Doc19. PubMed ID: 21289970
[TBL] [Abstract][Full Text] [Related]
14. Correlation Analysis of Clinician- and Patient-Reported Outcomes Among Japanese Adults with Atopic Dermatitis.
Saeki H; Kataoka Y; Etoh T; Katoh N; Teramukai S; Tajima Y; Fujita H; Ardeleanu M; Arima K
Dermatol Ther (Heidelb); 2024 Feb; 14(2):533-543. PubMed ID: 38326699
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
[TBL] [Abstract][Full Text] [Related]
16. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P.
Hon KL; Lam MC; Wong KY; Leung TF; Ng PC
Br J Dermatol; 2007 Nov; 157(5):922-5. PubMed ID: 17725670
[TBL] [Abstract][Full Text] [Related]
18. Nocturnal wrist movements are correlated with objective clinical scores and plasma chemokine levels in children with atopic dermatitis.
Hon KL; Lam MC; Leung TF; Kam WY; Lee KC; Li MC; Fok TF; Ng PC
Br J Dermatol; 2006 Apr; 154(4):629-35. PubMed ID: 16536804
[TBL] [Abstract][Full Text] [Related]
19. Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients.
Torisu-Itakura H; Anderson P; Piercy J; Pike J; Sakamoto A; Kabashima K
Curr Med Res Opin; 2022 Aug; 38(8):1401-1410. PubMed ID: 35787197
[TBL] [Abstract][Full Text] [Related]
20. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
Eyerich K; Gooderham MJ; Silvestre JF; Shumack SP; Mendes-Bastos P; Aoki V; Ortoncelli M; Silverberg JI; Teixeira HD; Chen SH; Calimlim BM; Takemoto S; Sancho C; Fritz B; Irvine AD
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):340-353. PubMed ID: 37669868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
